uniQure N.V. (0EE0.L)
| Previous close | 8.71 |
| Open | 8.63 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 8.19 - 8.70 |
| 52-week range | 4.94 - 22.20 |
| Volume | |
| Avg. volume | 2,359 |
| Market cap | 317.343M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | 1.20 |
| EPS (TTM) | 6.89 |
| Earnings date | 30 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswireuniQure Announces Closing of Sale of Manufacturing Facility to Genezen
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of the sale of its global manufacturing facility in Le
ZacksBiotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.
